Close Menu
TechCentralTechCentral

    Subscribe to the newsletter

    Get the best South African technology news and analysis delivered to your e-mail inbox every morning.

    Facebook X (Twitter) YouTube LinkedIn
    WhatsApp Facebook X (Twitter) LinkedIn YouTube
    TechCentralTechCentral
    • News

      Vodacom’s Maziv deal gets makeover ahead of crucial hearing

      18 July 2025

      Cut electricity prices for data centres: Andile Ngcaba

      18 July 2025

      Takealot taps Mr D to deliver toys, pet food and future growth

      18 July 2025

      ‘Oh, Ani!’: Elon’s edgy bot stirs ethical storm

      18 July 2025

      Trump U-turn on Nvidia spurs talk of grand bargain with China

      18 July 2025
    • World

      Grok 4 arrives with bold claims and fresh controversy

      10 July 2025

      Samsung’s bet on folding phones faces major test

      10 July 2025

      Bitcoin pushes higher into record territory

      10 July 2025

      OpenAI to launch web browser in direct challenge to Google Chrome

      10 July 2025

      Cupertino vs Brussels: Apple challenges Big Tech crackdown

      7 July 2025
    • In-depth

      The 1940s visionary who imagined the Information Age

      14 July 2025

      MultiChoice is working on a wholesale overhaul of DStv

      10 July 2025

      Siemens is battling Big Tech for AI supremacy in factories

      24 June 2025

      The algorithm will sing now: why musicians should be worried about AI

      20 June 2025

      Meta bets $72-billion on AI – and investors love it

      17 June 2025
    • TCS

      TCS+ | Samsung unveils significant new safety feature for Galaxy A-series phones

      16 July 2025

      TCS+ | MVNX on the opportunities in South Africa’s booming MVNO market

      11 July 2025

      TCS | Connecting Saffas – Renier Lombard on The Lekker Network

      7 July 2025

      TechCentral Nexus S0E4: Takealot’s big Post Office jobs plan

      4 July 2025

      TCS | Tech, townships and tenacity: Spar’s plan to win with Spar2U

      3 July 2025
    • Opinion

      A smarter approach to digital transformation in ICT distribution

      15 July 2025

      In defence of equity alternatives for BEE

      30 June 2025

      E-commerce in ICT distribution: enabler or disruptor?

      30 June 2025

      South Africa pioneered drone laws a decade ago – now it must catch up

      17 June 2025

      AI and the future of ICT distribution

      16 June 2025
    • Company Hubs
      • Africa Data Centres
      • AfriGIS
      • Altron Digital Business
      • Altron Document Solutions
      • Altron Group
      • Arctic Wolf
      • AvertITD
      • Braintree
      • CallMiner
      • CambriLearn
      • CYBER1 Solutions
      • Digicloud Africa
      • Digimune
      • Domains.co.za
      • ESET
      • Euphoria Telecom
      • Incredible Business
      • iONLINE
      • Iris Network Systems
      • LSD Open
      • NEC XON
      • Network Platforms
      • Next DLP
      • Ovations
      • Paracon
      • Paratus
      • Q-KON
      • SevenC
      • SkyWire
      • Solid8 Technologies
      • Telit Cinterion
      • Tenable
      • Vertiv
      • Videri Digital
      • Wipro
      • Workday
    • Sections
      • AI and machine learning
      • Banking
      • Broadcasting and Media
      • Cloud services
      • Contact centres and CX
      • Cryptocurrencies
      • Education and skills
      • Electronics and hardware
      • Energy and sustainability
      • Enterprise software
      • Fintech
      • Information security
      • Internet and connectivity
      • Internet of Things
      • Investment
      • IT services
      • Lifestyle
      • Motoring
      • Public sector
      • Retail and e-commerce
      • Science
      • SMEs and start-ups
      • Social media
      • Talent and leadership
      • Telecoms
    • Events
    • Advertise
    TechCentralTechCentral
    Home » In-depth » The next wave of Covid vaccines is coming

    The next wave of Covid vaccines is coming

    By Agency Staff20 May 2021
    Twitter LinkedIn Facebook WhatsApp Email Telegram Copy Link
    News Alerts
    WhatsApp

    There are more than 10 effective Covid-19 vaccines in use around the world, so it’s easy to forget those still in development. That’s a mistake.

    These candidates may be taking longer to arrive, but they’re essential to the pandemic fight. Most of the world is still unvaccinated, keeping the virus threat alive, and wherever it is able to spread unchecked there’s a risk of variants cropping up that can evade the protection offered by the current crop of shots. Governments need everything they can get and these shots offer the promise of billions of doses of reinforcements.

    Of the dozens of vaccine programmes in human testing, there are some standouts. Here are four of them, including their status, advantages and challenges.

    1. Novavax

    US-based Novavax already has positive data in hand from extensive studies of its vaccine in South Africa and the UK that show protection against the original virus strain and variants. A large US trial will reveal more data soon. While manufacturing and regulatory holdups pushed back the company’s potential regulatory filing from this quarter into the the third, the roll-out is finally in sight.

    Advantages: There’s solid evidence of efficacy for the shot, which uses tiny proteins to produce an immune response and a booster called an adjuvant to enhance it, and the company is laying groundwork to make many doses. Novavax made a deal earlier this year to provide a whopping 1.1 billion shots to Covax, the global procurement platform for low-income countries, on top of agreements with individual countries and licences for others to make its vaccine.

    Challenges: Most of the Covax doses will come from the Serum Institute of India, which has delayed exports to focus on India’s internal crisis. Also, Novavax’s manufacturing efforts have been held up by shortages of things like giant bags used to grow cells and it remains vulnerable to further similar disruptions.

    2. CureVac

    The German biotechnology firm started a large late-stage placebo-controlled study of its vaccine — which uses the same type of messenger RNA technology that powers the Pfizer-BioNTech and Moderna shots — in December. Recruitment is complete and the company hopes to release data and apply for authorisation before the end of June.

    Advantages: The success of the Pfizer-BioNTech and Moderna vaccines has raised expectations for shots using mRNA technology, and Curevac’s version may be a further improvement. The company modifies the RNA molecule differently, which lets it use a smaller dose. That will help it make more vaccines quickly, especially with the help of partnerships it formed with GlaxoSmithKline, Bayer and Novartis.

    Challenges: CureVac must prove that its lower dose provides enough protection. On the supply-chain front, mRNA-focused companies have faced an extra set of shortages of specialised equipment and ingredients because the technology they’re using is newer.

    3. Valneva

    The French company launched a unique final stage trial on 21 April. Instead of comparing vaccinated people to a group who receive a placebo and tracking illnesses, Valneva’s candidate will be tested head-to-head against AstraZeneca’s widely used shot in 4 000 people, and the study will measure and compare the immune responses via a blood test. If Valneva’s vaccine produces as many neutralising antibodies as AstraZeneca’s, it should theoretically protect against Covid. This approach will produce faster results, and the company hopes to apply for authorisation in the southern hemisphere spring.

    Advantages: As others scramble to adapt vaccines to variant strains, Valneva believes that its shot will hold up well from the start. That’s because it uses a non-infectious (inactive) whole virus to generate a broader immune response. Many vaccines target just the so-called spike protein of the virus that causes Covid, potentially leaving them more vulnerable to mutations.

    Challenges: Other efforts using inactive viruses such as the shot developed by China’s Sinovac Biotech have had less than stellar results. Additionally, the comparative trial may not sit well with regulators. There have been advances in understanding the immune response to Covid, and there’s precedent for such studies in other diseases. But it’s a bold way to try for initial approval. Valneva plans to conduct additional complementary tests and may need them.

    4. Sanofi and GlaxoSmithKline

    The companies intended to begin a definitive trial of a vaccine similar to Novavax’s last year. After early results showed it wasn’t potent enough, they had to make tweaks. That issue appears resolved; positive data from a new version emerged on 17 May, and a placebo-controlled final-stage trial will begin within a few weeks. The companies hope to reach the market in the fourth quarter.

    Advantages: The combined power of two of the world’s biggest vaccine manufacturers is an advantage in its own right. Sanofi already makes a flu shot with the same platform, while Glaxo has years of experience making adjuvant boosters like the one that will be used in the vaccine. Their logistical resources and know-how should mean a rapid roll-out upon approval. Delay has also allowed the companies to adapt. They will simultaneously test a formulation aimed at the South African variant and look at whether a lower dose of variant-targeting versions could serve as a booster for those inoculated with other vaccines.

    Challenges: Placebo-controlled trials are the gold standard, but they’re harder to conduct now. There’s little incentive to join a study in which you might not get a vaccine when approved shots are available, so recruitment may prove tricky and must focus on areas without broad access. Valneva may be gambling on blood tests for a quicker result, but Sanofi and Glaxo’s conservative approach may prove very time consuming.

    These are just a few of the vaccines in the works; there are many more on the way. Sanofi and Glaxo, for instance, are hedging their bets with an mRNA shot and a plant-based vaccine from Medicago, respectively, and the latter recently reported promising mid-stage data. Other developers hope to improve delivery: Vaxart is working on a tablet, and companies including Altimmune want to vaccinate with nasal sprays. With continued support, perhaps in the form of government effort to shore up supply chains or guidance on comparative trials, not to mention some good luck, this next wave can get the world from scarcity to abundance and a step closer to putting the pandemic behind us.  — Reported by Max Nisen, (c) 2021 Bloomberg LP



    CureVac GlaxoSmithKline Novavax Sanofi top Valneva
    Subscribe to TechCentral Subscribe to TechCentral
    Share. Facebook Twitter LinkedIn WhatsApp Telegram Email Copy Link
    Previous ArticleMicrosoft is killing off Internet Explorer for good
    Next Article Johannesburg announces big push towards renewable energy

    Related Posts

    18GW in unplanned breakdowns cripple Eskom

    2 November 2021

    Nersa kicks the Karpowership can down the road

    13 September 2021

    If you think South African load shedding is bad, try Zimbabwe’s

    13 September 2021
    Company News

    Vertiv to acquire custom rack solutions manufacturer

    18 July 2025

    SA businesses embrace gen AI – but strategy and skills are lagging

    17 July 2025

    Ransomware in South Africa: the human factor behind the growing crisis

    16 July 2025
    Opinion

    A smarter approach to digital transformation in ICT distribution

    15 July 2025

    In defence of equity alternatives for BEE

    30 June 2025

    E-commerce in ICT distribution: enabler or disruptor?

    30 June 2025

    Subscribe to Updates

    Get the best South African technology news and analysis delivered to your e-mail inbox every morning.

    © 2009 - 2025 NewsCentral Media

    Type above and press Enter to search. Press Esc to cancel.